Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:KCNN3-LAPTM4B

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: KCNN3-LAPTM4B
	FusionPDB ID: 41527
	FusionGDB2.0 ID: 41527
		Hgene	Tgene
	Gene symbol	KCNN3	LAPTM4B
	Gene ID	3782	55353
	Gene name	potassium calcium-activated channel subfamily N member 3	lysosomal protein transmembrane 4 beta
	Synonyms	KCa2.3\|SK3\|SKCA3\|ZLS3\|hSK3	LAPTM4beta\|LC27
	Cytomap	1q21.3	8q22.1
	Type of gene	protein-coding	protein-coding
	Description	small conductance calcium-activated potassium channel protein 3SKCa 3potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 3potassium intermediate/small conductance calcium-activated channel, subfamily N, member	lysosomal-associated transmembrane protein 4Blysosomal associated protein transmembrane 4 betalysosome-associated transmembrane protein 4-beta
	Modification date	20200329	20200313
	UniProtAcc	Q9UGI6 Main function of 5'-partner protein: FUNCTION: Forms a voltage-independent potassium channel activated by intracellular calcium (PubMed:31155282). Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin. {ECO:0000269\|PubMed:31155282}.	Q86VI4 Main function of 5'-partner protein: FUNCTION: Required for optimal lysosomal function (PubMed:21224396). Blocks EGF-stimulated EGFR intraluminal sorting and degradation. Conversely by binding with the phosphatidylinositol 4,5-bisphosphate, regulates its PIP5K1C interaction, inhibits HGS ubiquitination and relieves LAPTM4B inhibition of EGFR degradation (PubMed:25588945). Recruits SLC3A2 and SLC7A5 (the Leu transporter) to the lysosome, promoting entry of leucine and other essential amino acid (EAA) into the lysosome, stimulating activation of proton-transporting vacuolar (V)-ATPase protein pump (V-ATPase) and hence mTORC1 activation (PubMed:25998567). Plays a role as negative regulator of TGFB1 production in regulatory T cells (PubMed:26126825). Binds ceramide and facilitates its exit from late endosome in order to control cell death pathways (PubMed:26280656). {ECO:0000269\|PubMed:21224396, ECO:0000269\|PubMed:25588945, ECO:0000269\|PubMed:25998567, ECO:0000269\|PubMed:26126825, ECO:0000269\|PubMed:26280656}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000358505, ENST00000271915, ENST00000361147, ENST00000515643,	ENST00000445593, ENST00000521545,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 6 X 5=180	14 X 8 X 8=896
	# samples	8	16
	** MAII score	log2(8/180*10)=-1.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(16/896*10)=-2.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: KCNN3 [Title/Abstract] AND LAPTM4B [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: KCNN3 [Title/Abstract] AND LAPTM4B [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	KCNN3(154794565)-LAPTM4B(98817581), # samples:1
Anticipated loss of major functional domain due to fusion event.	KCNN3-LAPTM4B seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KCNN3-LAPTM4B seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KCNN3-LAPTM4B seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KCNN3-LAPTM4B seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KCNN3-LAPTM4B seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	LAPTM4B	GO:0032509	endosome transport via multivesicular body sorting pathway	25588945
Tgene	LAPTM4B	GO:0032911	negative regulation of transforming growth factor beta1 production	26126825

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:154794565/chr8:98817581)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across KCNN3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across LAPTM4B (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000271915	KCNN3	chr1	154794565	-	ENST00000445593	LAPTM4B	chr8	98817581	+	3466	1345	58	1926	622
ENST00000271915	KCNN3	chr1	154794565	-	ENST00000521545	LAPTM4B	chr8	98817581	+	1927	1345	58	1926	623
ENST00000361147	KCNN3	chr1	154794565	-	ENST00000445593	LAPTM4B	chr8	98817581	+	2366	245	131	826	231
ENST00000361147	KCNN3	chr1	154794565	-	ENST00000521545	LAPTM4B	chr8	98817581	+	827	245	131	826	232

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000271915	ENST00000445593	KCNN3	chr1	154794565	-	LAPTM4B	chr8	98817581	+	0.009146508	0.9908535
ENST00000271915	ENST00000521545	KCNN3	chr1	154794565	-	LAPTM4B	chr8	98817581	+	0.03907387	0.9609261
ENST00000361147	ENST00000445593	KCNN3	chr1	154794565	-	LAPTM4B	chr8	98817581	+	0.000399952	0.9996001
ENST00000361147	ENST00000521545	KCNN3	chr1	154794565	-	LAPTM4B	chr8	98817581	+	0.000518649	0.9994814

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for KCNN3-LAPTM4B

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
KCNN3	chr1	154794565	LAPTM4B	chr8	98817581	1345	428	LLGLIIAYHTREVQIINAVVLLILLS
KCNN3	chr1	154794565	LAPTM4B	chr8	98817581	245	37	LLGLIIAYHTREVQIINAVVLLILLS

Top

Potential FusionNeoAntigen Information of KCNN3-LAPTM4B in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

KCNN3-LAPTM4B_154794565_98817581.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:02	REVQIINA	0.9998	0.5451	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B45:01	REVQIINA	0.9996	0.7396	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:01	YHTREVQI	0.9985	0.8139	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B38:02	YHTREVQI	0.9978	0.9217	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B38:01	YHTREVQI	0.9977	0.9227	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B41:01	REVQIINA	0.9922	0.8506	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B52:01	VQIINAVV	0.9657	0.8782	12	20
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:01	REVQIINA	0.9653	0.659	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:37	YHTREVQI	0.8923	0.5811	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B45:01	REVQIINAV	0.9985	0.918	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:02	REVQIINAV	0.9985	0.6189	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:01	YHTREVQII	0.9968	0.7302	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:06	YHTREVQII	0.9965	0.6967	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:06	TREVQIINA	0.9962	0.7511	9	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B38:01	YHTREVQII	0.9943	0.8395	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B38:02	YHTREVQII	0.9941	0.8483	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:01	REVQIINAV	0.9938	0.5008	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B13:02	REVQIINAV	0.9903	0.9318	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B48:01	REVQIINAV	0.989	0.6512	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B13:01	REVQIINAV	0.988	0.9673	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B48:01	VQIINAVVL	0.9442	0.5012	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B47:01	REVQIINAV	0.9189	0.6735	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:24	VQIINAVVL	0.8936	0.6608	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B44:03	REVQIINAV	0.8614	0.9582	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:13	REVQIINAV	0.7983	0.9828	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B41:01	REVQIINAV	0.7921	0.9606	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:01	VQIINAVVL	0.775	0.9594	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:03	VQIINAVVL	0.7049	0.7575	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:01	REVQIINAV	0.6593	0.7357	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:13	VQIINAVVL	0.6315	0.9588	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B13:02	VQIINAVVL	0.61	0.6056	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B13:01	VQIINAVVL	0.5953	0.9373	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:37	YHTREVQII	0.5688	0.5013	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:10	VQIINAVVL	0.5628	0.6114	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B18:01	REVQIINAV	0.5547	0.9326	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:37	VQIINAVVL	0.5168	0.6151	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B52:01	REVQIINAV	0.2412	0.9198	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B52:01	VQIINAVVL	0.1169	0.7607	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-A30:08	HTREVQIINA	0.9874	0.8655	8	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B48:01	REVQIINAVVL	0.9986	0.5362	10	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:13	REVQIINAVVL	0.966	0.972	10	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:06	REVQIINA	0.9999	0.6904	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:05	YHTREVQI	0.9973	0.7834	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:06	REVQIINAV	0.9997	0.8359	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:12	YHTREVQII	0.996	0.7426	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:05	YHTREVQII	0.9943	0.6965	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B44:10	REVQIINAV	0.9913	0.5944	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B48:03	REVQIINAV	0.9898	0.5872	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B73:01	TREVQIINA	0.9848	0.7482	9	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:03	REVQIINAV	0.9676	0.5208	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:04	VQIINAVVL	0.9152	0.8899	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:08	REVQIINAV	0.846	0.9603	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:09	VQIINAVVL	0.8176	0.845	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:05	VQIINAVVL	0.5786	0.9524	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C07:29	AYHTREVQI	0.4159	0.8981	6	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C07:13	AYHTREVQI	0.3752	0.911	6	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B14:03	YHTREVQII	0.2563	0.5336	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:06	REVQIINAVV	0.9989	0.8144	10	20
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B38:05	YHTREVQI	0.9977	0.9227	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:09	YHTREVQI	0.983	0.6005	7	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:04	REVQIINA	0.9653	0.659	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:05	REVQIINA	0.9653	0.659	10	18
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:04	REVQIINAV	0.998	0.8963	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-A68:02	EVQIINAVV	0.9975	0.6864	11	20
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:31	YHTREVQII	0.9973	0.7341	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B38:05	YHTREVQII	0.9943	0.8395	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:36	REVQIINAV	0.9939	0.5257	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:49	REVQIINAV	0.9932	0.5284	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-A69:01	EVQIINAVV	0.9931	0.7012	11	20
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:12	REVQIINAV	0.9898	0.5872	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:73	VQIINAVVL	0.9457	0.9185	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:53	VQIINAVVL	0.9253	0.8388	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B41:03	REVQIINAV	0.9186	0.8511	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:30	VQIINAVVL	0.9069	0.8213	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:54	VQIINAVVL	0.8864	0.8258	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:68	VQIINAVVL	0.8693	0.722	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B44:07	REVQIINAV	0.8614	0.9582	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B44:13	REVQIINAV	0.8614	0.9582	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B44:26	REVQIINAV	0.8614	0.9582	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:02	VQIINAVVL	0.8279	0.9612	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:31	VQIINAVVL	0.7902	0.9582	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B39:02	REVQIINAV	0.7689	0.9816	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B18:11	REVQIINAV	0.6981	0.9344	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:05	REVQIINAV	0.6593	0.7357	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B50:04	REVQIINAV	0.6593	0.7357	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B18:05	REVQIINAV	0.5547	0.9326	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B18:06	REVQIINAV	0.5396	0.9558	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B48:02	VQIINAVVL	0.534	0.8512	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B35:13	VQIINAVVL	0.524	0.8771	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C07:04	YHTREVQII	0.5095	0.8939	7	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B18:03	REVQIINAV	0.4871	0.9282	10	19
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B15:09	VQIINAVVL	0.3913	0.7223	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C07:04	AYHTREVQI	0.3376	0.95	6	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B35:28	VQIINAVVL	0.2871	0.8723	12	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C14:03	AYHTREVQI	0.1197	0.9578	6	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C14:02	AYHTREVQI	0.1197	0.9578	6	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-C06:06	AYHTREVQI	0.1177	0.9873	6	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:36	REVQIINAVV	0.9726	0.6219	10	20
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B40:04	REVQIINAVVL	0.9993	0.7545	10	21
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	HLA-B41:03	REVQIINAVVL	0.828	0.7371	10	21

Top

Potential FusionNeoAntigen Information of KCNN3-LAPTM4B in HLA II

KCNN3-LAPTM4B_154794565_98817581.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1102	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1116	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1121	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1148	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1165	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1170	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1301	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1308	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1309	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1317	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1317	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1319	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1322	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1327	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1335	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1343	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1351	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1352	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1353	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1359	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1361	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1364	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1368	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1369	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1370	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1372	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1376	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1379	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1380	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1383	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1384	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1387	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1391	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1392	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1398	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1416	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1416	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1416	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1457	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1501	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1501	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1501	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1502	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1502	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1502	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1503	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1503	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1504	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1504	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1504	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1505	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1505	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1505	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1506	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1506	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1506	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1507	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1507	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1507	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1508	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1508	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1508	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1509	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1509	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1509	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1510	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1510	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1510	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1511	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1511	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1512	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1512	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1512	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1513	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1513	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1513	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1514	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1514	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1514	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1515	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1516	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1516	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1516	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1518	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1518	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1518	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1519	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1519	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1519	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1520	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1520	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1520	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1521	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1521	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1521	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1522	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1522	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1522	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1524	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1524	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1524	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1526	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1526	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1526	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1528	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1528	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1528	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1529	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1529	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1530	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1530	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1530	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1531	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1531	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1531	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1532	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1532	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1532	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1533	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1533	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1533	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1535	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1535	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1535	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1536	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1536	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1536	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1537	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1537	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1537	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1538	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1538	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1538	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1539	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1539	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1539	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1540	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1540	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1540	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1541	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1541	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1541	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1542	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1542	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1542	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1543	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1543	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1543	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1544	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1544	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1544	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1545	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1545	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1545	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1546	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1546	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1546	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1547	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1547	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1547	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1548	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1548	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1548	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1549	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1549	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB1-1549	GLIIAYHTREVQIIN	2	17
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB5-0202	LLGLIIAYHTREVQI	0	15
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB5-0202	LGLIIAYHTREVQII	1	16
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1345	DRB5-0204	LLGLIIAYHTREVQI	0	15

Top

Fusion breakpoint peptide structures of KCNN3-LAPTM4B

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
747	AYHTREVQIINAVV	KCNN3	LAPTM4B	chr1	154794565	chr8	98817581	1345

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of KCNN3-LAPTM4B

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	747	AYHTREVQIINAVV	-7.9962	-8.1096
HLA-B14:02	3BVN	747	AYHTREVQIINAVV	-5.70842	-6.74372
HLA-B52:01	3W39	747	AYHTREVQIINAVV	-6.83737	-6.95077
HLA-B52:01	3W39	747	AYHTREVQIINAVV	-4.4836	-5.5189
HLA-A11:01	4UQ2	747	AYHTREVQIINAVV	-10.0067	-10.1201
HLA-A11:01	4UQ2	747	AYHTREVQIINAVV	-9.03915	-10.0745
HLA-A24:02	5HGA	747	AYHTREVQIINAVV	-6.56204	-6.67544
HLA-A24:02	5HGA	747	AYHTREVQIINAVV	-5.42271	-6.45801
HLA-B44:05	3DX8	747	AYHTREVQIINAVV	-7.85648	-8.89178
HLA-B44:05	3DX8	747	AYHTREVQIINAVV	-5.3978	-5.5112
HLA-A02:01	6TDR	747	AYHTREVQIINAVV	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of KCNN3-LAPTM4B

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	10	18	REVQIINA	GAAGTCCAGATCATCAATGCTGTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	10	19	REVQIINAV	GAAGTCCAGATCATCAATGCTGTGGTA
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	10	20	REVQIINAVV	GAAGTCCAGATCATCAATGCTGTGGTACTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	10	21	REVQIINAVVL	GAAGTCCAGATCATCAATGCTGTGGTACTGTTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	11	20	EVQIINAVV	GTCCAGATCATCAATGCTGTGGTACTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	12	20	VQIINAVV	CAGATCATCAATGCTGTGGTACTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	12	21	VQIINAVVL	CAGATCATCAATGCTGTGGTACTGTTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	6	15	AYHTREVQI	TACCACACACGTGAAGTCCAGATCATC
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	7	15	YHTREVQI	CACACACGTGAAGTCCAGATCATC
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	7	16	YHTREVQII	CACACACGTGAAGTCCAGATCATCAAT
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	8	18	HTREVQIINA	ACACGTGAAGTCCAGATCATCAATGCTGTG
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	9	18	TREVQIINA	CGTGAAGTCCAGATCATCAATGCTGTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	0	15	LLGLIIAYHTREVQI	TTGGGCTTGATCATCGCCTACCACACACGTGAAGTCCAGATCATC
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	1	16	LGLIIAYHTREVQII	GGCTTGATCATCGCCTACCACACACGTGAAGTCCAGATCATCAAT
KCNN3-LAPTM4B	chr1	154794565	chr8	98817581	2	17	GLIIAYHTREVQIIN	TTGATCATCGCCTACCACACACGTGAAGTCCAGATCATCAATGCT

Top

Information of the samples that have these potential fusion neoantigens of KCNN3-LAPTM4B

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	KCNN3-LAPTM4B	chr1	154794565	ENST00000271915	chr8	98817581	ENST00000445593	TCGA-CG-4449-01A

Top

Potential target of CAR-T therapy development for KCNN3-LAPTM4B

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000445593

163_183

318.0

Transmembrane

Helical

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000445593

191_211

318.0

Transmembrane

Helical

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000445593

244_264

318.0

Transmembrane

Helical

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000521545

117_137

227.0

Transmembrane

Helical

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000521545

163_183

227.0

Transmembrane

Helical

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000521545

191_211

227.0

Transmembrane

Helical

Tgene

LAPTM4B

chr1:154794565

chr8:98817581

ENST00000521545

244_264

227.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to KCNN3-LAPTM4B

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to KCNN3-LAPTM4B

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)